These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38387938)

  • 41. Adoptive cell therapy in multiple Myeloma.
    Vallet S; Pecherstorfer M; Podar K
    Expert Opin Biol Ther; 2017 Dec; 17(12):1511-1522. PubMed ID: 28857616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Natural killer cells as a double-edged sword in cancer immunotherapy: A comprehensive review from cytokine therapy to adoptive cell immunotherapy.
    Wu Y; Li J; Jabbarzadeh Kaboli P; Shen J; Wu X; Zhao Y; Ji H; Du F; Zhou Y; Wang Y; Zhang H; Yin J; Wen Q; Cho CH; Li M; Xiao Z
    Pharmacol Res; 2020 May; 155():104691. PubMed ID: 32070721
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimizing NK Cell-Based Immunotherapy in Myeloid Leukemia: Abrogating an Immunosuppressive Microenvironment.
    Kaweme NM; Zhou F
    Front Immunol; 2021; 12():683381. PubMed ID: 34220833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Individualized genetic makeup that controls natural killer cell function influences the efficacy of isatuximab immunotherapy in patients with multiple myeloma.
    Sun H; Martin TG; Marra J; Kong D; Keats J; Macé S; Chiron M; Wolf JL; Venstrom JM; Rajalingam R
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34272304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natural Killer Cell Immunotherapy for Osteosarcoma.
    Tullius BP; Setty BA; Lee DA
    Adv Exp Med Biol; 2020; 1257():141-154. PubMed ID: 32483737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
    Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
    Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Preferential proliferation of natural killer cells with bone marrow mononuclear cells in multiple myeloma].
    Tsuji K; Tsubaki K
    Nihon Rinsho Meneki Gakkai Kaishi; 1995 Feb; 18(1):60-9. PubMed ID: 7553040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Current Perspectives on "Off-The-Shelf" Allogeneic NK and CAR-NK Cell Therapies.
    Heipertz EL; Zynda ER; Stav-Noraas TE; Hungler AD; Boucher SE; Kaur N; Vemuri MC
    Front Immunol; 2021; 12():732135. PubMed ID: 34925314
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Enhancing the Activation and Releasing the Brakes: A Double Hit Strategy to Improve NK Cell Cytotoxicity Against Multiple Myeloma.
    Tognarelli S; Wirsching S; von Metzler I; Rais B; Jacobs B; Serve H; Bader P; Ullrich E
    Front Immunol; 2018; 9():2743. PubMed ID: 30542346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Challenges to the broad application of allogeneic natural killer cell immunotherapy of cancer.
    Kennedy PR; Felices M; Miller JS
    Stem Cell Res Ther; 2022 Apr; 13(1):165. PubMed ID: 35414042
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hypoxia induced impairment of NK cell cytotoxicity against multiple myeloma can be overcome by IL-2 activation of the NK cells.
    Sarkar S; Germeraad WT; Rouschop KM; Steeghs EM; van Gelder M; Bos GM; Wieten L
    PLoS One; 2013; 8(5):e64835. PubMed ID: 23724099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression.
    Giuliani M; Janji B; Berchem G
    Oncotarget; 2017 Apr; 8(14):24031-24044. PubMed ID: 28199990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cellular immunotherapy in multiple myeloma.
    Vo MC; Lakshmi TJ; Jung SH; Cho D; Park HS; Chu TH; Lee HJ; Kim HJ; Kim SK; Lee JJ
    Korean J Intern Med; 2019 Sep; 34(5):954-965. PubMed ID: 30754964
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural killer cell-based strategies for immunotherapy of cancer.
    Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
    Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors.
    Piccinelli S; Romee R; Shapiro RM
    Semin Hematol; 2023 Jan; 60(1):42-51. PubMed ID: 37080710
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
    Lin C; Horwitz ME; Rein LAM
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613644
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition.
    Petillo S; Capuano C; Molfetta R; Fionda C; Mekhloufi A; Pighi C; Antonangeli F; Zingoni A; Soriani A; Petrucci MT; Galandrini R; Paolini R; Santoni A; Cippitelli M
    Cell Death Dis; 2021 Sep; 12(9):836. PubMed ID: 34482362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.
    Sanchez CE; Dowlati EP; Geiger AE; Chaudhry K; Tovar MA; Bollard CM; Cruz CRY
    Transplant Cell Ther; 2021 Jan; 27(1):21-35. PubMed ID: 33007496
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
    Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.